PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer.
Publication/Presentation Date
6-1-2018
Abstract
Palbociclib has been shown to be a highly effective therapy in hormone receptor positive metastatic breast cancer when used in combination with letrozole or fulvestrant. Grade 3/4 neutropenia is a common side effect although febrile neutropenia is relatively uncommon. Insufficient data exist to describe the hematological safety of palbociclib in African American women (AAW) known to have a high incidence of benign ethnic neutropenia (BEN). PALOMA 1, 2 and 3, the initial phase II/III studies that led to the U.S. Food and Drug Administration (FDA) approval of palbociclib in metastatic breast cancer, only included participants with baseline absolute neutrophil count (ANC) of 1500/mm
Volume
10
First Page
190
Last Page
192
ISSN
2451-8654
Published In/Presented At
Lynce, F., Saleh, M., Shajahan-Haq, A., Gallagher, C., Dilawari, A., Hahn, O., Abu-Khalaf, M., Cai, L., Pohlmann, P., Mohebtash, M., Kamugisha, L., & Isaacs, C. (2018). PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer. Contemporary clinical trials communications, 10, 190–192. https://doi.org/10.1016/j.conctc.2018.05.012
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
30009277
Department(s)
Administration and Leadership
Document Type
Article